FDA Claims Sole Authority Over Naming Of US-Licensed Biologics

Deferring to nonproprietary names established by US Pharmacopeia without exercising independent judgment ‘would be untenable,’ FDA says in citizen petition response to industry; agency offers statutory defense of decision to require distinguishable suffixes for all novel biologics and biosimilars.

The US FDA asserts its full authority over biological product nonproprietary naming and justifies its final guidance requirement for distinguishable, nonmeaningful suffixes in a recent response to several industry citizen petitions.

A response to the Generic Pharmaceutical Association (GPhA), Sandoz Inc. and Johnson & Johnson lays out...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics